Anti-interleukin-5 monoclonal antibodies: preclinical and clinical evidence in asthma models.
about
Clinical usefulness of mepolizumab in severe eosinophilic asthmaCurcumin and HealthTreatment of allergic asthma: modulation of Th2 cells and their responsesInnate immunity is a key factor for the resolution of inflammation in asthmaRole of TNFalpha in pulmonary pathophysiology.Eosinophils: changing perspectives in health and disease.Simvastatin Inhibits IL-5-Induced Chemotaxis and CCR3 Expression of HL-60-Derived and Human Primary EosinophilsEosinophils contribute to the resolution of lung-allergic responses following repeated allergen challenge.Allergic pulmonary inflammation in mice is dependent on eosinophil-induced recruitment of effector T cellsA cell-impermeable cyclosporine A derivative reduces pathology in a mouse model of allergic lung inflammation.IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis.Targeting eosinophils in asthmaGATA transcription factors regulate the expression of the human eosinophil-derived neurotoxin (RNase 2) gene.Functionally competent eosinophils differentiated ex vivo in high purity from normal mouse bone marrow.Post-allergen challenge inhibition of poly(ADP-ribose) polymerase harbors therapeutic potential for treatment of allergic airway inflammation.Pneumoviruses infect eosinophils and elicit MyD88-dependent release of chemoattractant cytokines and interleukin-6.Eosinophils and their interactions with respiratory virus pathogens.An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice.Cytokine antagonists for the treatment of asthma: progress to date.Oligonucleotides: a multi-targeted approach for the treatment of respiratory diseases.Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor.Monoclonal antibodies for asthma and chronic obstructive pulmonary disease.Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations.Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma.Analysis of patents on anti-allergic therapies issued in China from 1988 to 2008.Eosinophils infiltrate thyroids, but have no apparent role in induction or resolution of experimental autoimmune thyroiditis in interferon-gamma(-/-) mice.Female mice are more susceptible to the development of allergic airway inflammation than male mice.Effects of a low-molecular-weight CCR-3 antagonist on chronic experimental asthma.Plasminogen activator inhibitor-2 (PAI-2) in eosinophilic leukocytes.
P2860
Q26746215-65B498B4-A981-4F9D-827B-185B2CDDB7B5Q26765493-5EF42A17-658A-434D-88BF-4CB04A3ACA11Q27011823-6DE5F912-1FBB-41E8-BAAA-9E54E1E3C125Q34465047-30F2B3BE-E14F-4521-A728-5BB0DBE584BFQ35094582-26499089-6852-4C2A-B341-283B29A15141Q35170969-C556C6DC-3AE0-4D8F-9A0E-9CAC1D659A50Q36044812-ADF892D0-90F2-41DE-A146-9C5A605DB691Q36105237-3A12536B-90CD-43A8-B5D2-30C96F4CAC1CQ36509887-0E7EE2C9-FC47-4DAC-9A4F-09D24043194CQ36701411-27B6DF8B-8FF8-4970-939B-F26B53DCBFA4Q36849075-58BF5AE2-9317-4E3C-AC64-A5616CD8E5EBQ37056577-518FD90A-8529-496E-AA1B-7AF81F2CBDBCQ37176457-7AA1F1B9-F9CA-4E97-B341-53AAAFA1B3C7Q37187744-3645DE04-1DA1-4F11-8A8E-0C7D52E30361Q37339488-22E258F8-E52C-4BFA-B111-314468508D15Q37372816-75725EE3-07C3-4D2A-92F2-84B1418203CCQ37421366-3C59A689-9FCB-4B3B-B64F-98050F16A38CQ37522916-D007F8F0-CB19-44FE-A51C-A281B14C4986Q37583895-160768EE-78C8-47EC-85EC-8B776E594A38Q37937557-85A2036A-50B4-43BD-8E5E-E849833278C2Q37957225-E84FB8C1-91A0-49D6-9DAD-280D4FF19AA3Q38071124-7F442AE8-6C08-450C-9B8A-4E9E9542B89FQ39189229-8FA07A18-88F3-4C62-9F67-84230752E393Q41605623-4B602301-CD45-4EFD-A613-3C11DBDA13F8Q43061739-0465F059-217E-4BD7-BF7B-F90E3F57361AQ43257498-0470DEEA-EA95-4428-8DA9-19C1FE72EE5EQ46811044-D24CD844-7830-4E41-BB95-2B0089F2516AQ47325098-3D375759-2083-44FD-BC3E-741DBA72107FQ47950786-7352625F-AFD1-463C-8CFA-A10840A6A04B
P2860
Anti-interleukin-5 monoclonal antibodies: preclinical and clinical evidence in asthma models.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Anti-interleukin-5 monoclonal ...... cal evidence in asthma models.
@ast
Anti-interleukin-5 monoclonal ...... cal evidence in asthma models.
@en
type
label
Anti-interleukin-5 monoclonal ...... cal evidence in asthma models.
@ast
Anti-interleukin-5 monoclonal ...... cal evidence in asthma models.
@en
prefLabel
Anti-interleukin-5 monoclonal ...... cal evidence in asthma models.
@ast
Anti-interleukin-5 monoclonal ...... cal evidence in asthma models.
@en
P2860
P356
P1476
Anti-interleukin-5 monoclonal ...... cal evidence in asthma models.
@en
P2093
Maggie J Leckie
P2860
P2888
P304
P356
10.1007/BF03256653
P577
2003-01-01T00:00:00Z